Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 5/2016

Open Access 01-10-2016 | Central Nervous System and Cognition (SS Spudich, Section Editor)

Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals

Authors: Jonathan Underwood, Alan Winston

Published in: Current HIV/AIDS Reports | Issue 5/2016

Login to get access

Abstract

Antiretroviral therapy has revolutionised the treatment for people living with HIV (PLWH). Where antiretroviral coverage is high, the treatment paradigm for HIV-disease is now one of managing the long-term consequences of the virus and its treatment rather than the consequences of untreated HIV-disease such as immunosuppression and opportunistic infections. One such long-term consequence is HIV-associated cognitive impairment which is reported to occur in up to 50 % of treated PLWH and has been associated with poorer outcomes. Given the ageing cohort and increased frequency of comorbidities, the prevalence of symptomatic cognitive impairment may increase with time. High quality evidence for management strategies including screening, diagnosis and treatment of HIV-associated cognitive impairment are lacking and in general guidelines are based on best clinical practice. In this article, we assessed recent guidelines concerning the management of HIV-associated cognitive impairment by performing a systematic review of the MEDLINE database using PubMed. We report that, in general, guidelines from around the world regarding the management of HIV-associated cognitive impairment are converging. Screening is generally not recommended in asymptomatic PLWH. Diagnosis of HIV-associated cognitive impairment should be made only after a comprehensive assessment and exclusion of other potential causes. Antiretroviral therapy forms the cornerstone of management of HIV-associated cognitive impairment and should be guided by plasma and cerebrospinal fluid (CSF) genotype(s).
Literature
1.
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28:1193–202.CrossRefPubMedPubMedCentral
2.
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology American Academy of Neurology. 2010;75:2087–96.
3.
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915–21.CrossRefPubMed
4.
5.
Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97.CrossRefPubMed
6.•
Winston A, Amin J, Clarke A, Else L, Amara A, Owen A, et al. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect Dis. 2015;60:1026–32. Interesting sub-study of the ENCORE study showing the CSF virological efficacy of 400 mg efavirenz OD and complicated non-dose dependent pharmacokinetics of its metabolite 8-OH that has been shown to exhibit significant neurotoxicity.PubMed
7.
Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV‐1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819–25.CrossRefPubMedPubMedCentral
8.
Cysique LA, Moffat K, Moore DM, Lane TA, Davies NWS, Carr A, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS ONE. 2013;8:e61738.CrossRefPubMedPubMedCentral
9.
Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS [Internet]. 2015;29:253–61.CrossRef
10.
11.
Churchill D, Waters L, Ahmed N, Angus B, Boffito M. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. 2015.
12.
Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 2011;13:1–44.CrossRef
13.
EACS Guidelines. 7 ed. Lundgren JD, Gatell JM, Furrer H, Rockstroh J, editors. eacsociety.org. European AIDS Clinical Society (EACS); 2014.
14.
EACS Guidelines. 8 ed. Lundgren JD, Ryom L, Gatell JM, Furrer H, Rockstroh J, editors. eacsociety.org. European AIDS Clinical Society (EACS); 2015.
15.
Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L’Hénaff M, et al. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc. 2014;17:19034.
16.
International Advisory Panel on HIV Care Continuum Optimization. IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents. J Int Assoc Provid AIDS Care. 2015;14 Suppl 1:S3–S34.CrossRef
17.
Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA Panel. JAMA. 2014;312:410–25.
18.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2013;58:e1–e34.CrossRefPubMed
19.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012;35:113–59.
20.
Antinori A, Marcotullio S, Andreoni M, Ammassari A, d’Arminio Monforte A, Galli M, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol. 2015;38:299–328.
21.
Korean Society for AIDS. The 2015 clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect Chemother. 2015;47:205–11.CrossRef
22.
Rouleau D, Fortin C, Trottier B, Lalonde R, Lapointe N, Côté P, et al. Antiretroviral therapy for adults infected with HIV: guidelines for health care professionals from the Quebec HIV care committee. Can J Infect Dis Med Microbiol. 2011;22:52–60.PubMedPubMedCentral
23.
Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12:12.CrossRefPubMedPubMedCentral
24.
25.
26.
World Health Organization. WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what’s new. WHO. World Health Organization; 2015.
27.
World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014.
28.
Geneva: World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization; 2015.
29.••
Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53:836–42. Excellent review focusing on the complexities of screening for cognitive impairment in HIV-positive populations. Useful summary of appropriate screening tools.CrossRefPubMedPubMedCentral
30.••
Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56:1004–17. Thorough review of the management of HIV-associated cognitive impairment. Again, a useful summary of the pros and cons of potential screening tools.
31.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99.CrossRefPubMedPubMedCentral
32.
Lin JS, O’Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:601–12.
33.
Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:791–7.
34.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMed
35.
36.••
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. Important study demonstrating the benefit of early initiation of antiretroviral therapy that has changed guidelines worldwide.CrossRef
37.
38.
Evering TH, Applebaum A, La Mar M, Garmon D, Dorfman D, Markowitz M. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection. AIDS. 2016;30:203–10.CrossRefPubMed
39.
Wright E, Grund B, Robertson K, Price RW, Group FTISNS. No difference between the effects of immediate versus deferred ART on neuropsychological test performance in HIV-positive adults with CD4+ cell counts above 500 cells/μl: the Strategic Timing of Anti-Retroviral Treatment (START) Neurology Substudy. 15th European AIDS Conference. 2015.
40.
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.CrossRefPubMedPubMedCentral
Metadata
Title
Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals
Authors
Jonathan Underwood
Alan Winston
Publication date
01-10-2016
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 5/2016
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0324-x

Other articles of this Issue 5/2016

Current HIV/AIDS Reports 5/2016 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

HIV Testing Services in Africa: Are They Sustainable?

Co-infections and Comorbidity (S Naggie, Section Editor)

Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV

The Global Epidemic (SH Vermund, Section Editor)

Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets

The Global Epidemic (SH Vermund, Section Editor)

Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

Co-infections and Comorbidity (S Naggie, Section Editor)

HIV, Aging, and Viral Coinfections: Taking the Long View
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits